Six years follow-up of Type 1 Retinopathy of Prematurity (ROP) Treated with Intravitreal Injection of Ranibizumab and Bevacizumab

Abstract Purpose To investigate biometric and refractive results in patients with type 1 ROP treated by intravitreal injection(IVI) of Ranibizumab(R) and Bevacizumab (B) at the corrected age of six. Methods This is a monocenter retrospective study. The infants diagnosed with type 1 ROP and treated with IVI of ranibizumab or bevacizumab as the first therapy were included. We analyzed the difference structural and functional between the two groups and comparing it with the previous study that when these children were in the age of one and three. Results Sixty eyes were enrolled. In biometric outcomes, there is still deeper anterior chamber and thinner lens thickness in the Ranibizumab group as previous reported at the age of three. In the refractory aspect, the eyes treated with bevacizumab had higher myopia at the age of one and three; however, at the age of six, a similar incidence of high myopia was observed in the two groups. Conclusions In the corrected age of six, the eyes treated with IVI Ranibizumab were associated with deeper anterior chamber and thinner lens thickness. Interestingly, emmtropization process brought similar incidence of high myopia in the age of six, which was different from the younger age.